# US 11,439,607 B2 · Use of senicapoc for treatment of neuropathic pain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,439,607 B2
- Document ID: US11439607B2
- Status: Granted
- Kind: B2
- Application number: 16/344,645
- Filed: 2017-10-23
- Published: 2020-02-13
- Granted: 2022-09-13
- Earliest claimed: 2016-10-25
- Assignees: Paracelsus Neuroscience I, LLC
- Applicants: Paracelsus Neuroscience I, LLC
- Inventors: Roland Staal; Thomas Möller
- Web page: https://patentgrep.com/patent/US11439607B2

## CPC

- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/02: without antiinflammatory effect
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method is disclosed of treating pain with senicapoc, a potent Ca2+-activated K+ channel, KCa3.1 antagonist in CNS-resident microglia. Senicapoc is shown to cause in a decrease of IL-1β and NO release from microglia cells vivo and in vitro. Because of contribution of KCa3.1 to neuropathological processes, senicapoc is useful in the treatment of chronic, neuropathic, visceral, and inflammatory pain and the reversal of tactile allodynia.

## Claims

### Claim 1

A method of inhibiting KCa3.1 calcium activated potassium channels on microglia in the central nervous system, satellite glia in the dorsal root ganglia or peripheral immune cells in a mammal suffering from neuropathic pain consisting of the administration of an amount of senicapoc sufficient to achieve at least 50% inhibition of the potassium channel KCa3.1 on microglia in the central nervous system, satellite glia in the dorsal root ganglia or peripheral immune cells, wherein the inhibition of microglia KCa3.1 channels treats neuropathic pain.

### Claim 2 (depends on 1)

The method of claim 1 wherein the administration of senicapoc comprises a dosage form selected from an oral tablet, an oral capsule, a powder for dissolution or suspension in a drinkable liquid, and an injectable dosage form.